Российский кардиологический журнал (Apr 2022)

Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial

  • Yu. M. Lopatin,
  • G. P. Arutyunov,
  • A. S. Ametov,
  • F. T. Ageev,
  • M. B. Antsiferov,
  • O. L. Barbarash,
  • S. V. Villevalde,
  • N. G. Vinogradova,
  • G. R. Galstyan,
  • A. S. Galyavich,
  • S. R. Gilyarevsky,
  • M. G. Glezer,
  • I. V. Zhirov,
  • M. V. Ilyin,
  • A. Yu. Lebedeva,
  • S. V. Nedogoda,
  • V. V. Salukhov,
  • E. I. Tarlovskaya,
  • S. N. Tereshchenko,
  • I. V. Fomin,
  • Yu. Sh. Khalimov,
  • D. V. Cherkashin

DOI
https://doi.org/10.15829/1560-4071-2022-4945
Journal volume & issue
Vol. 27, no. 3

Abstract

Read online

An online expert meeting held on November 17, 2021 reviewed the results of the randomized, double-blind, multinational, parallel-group EMPULSE trial, evaluating the clinical benefit and safety of the sodium-glucose co-transporter-2 inhibitor (SGLT2i) empagliflozin compared with placebo in patients hospitalized with acute decompensated heart failure (ADHF). Patients were included in the study regardless of ejection fraction (EF) and the presence of diabetes and randomized during hospitalization after stabilization. In addition, the EMPULSE trial used a composite result analyzed using a stratified benefit ratio — Win Ratio analysis. There is evidence of clinical benefit of empagliflozin in hospitalized patients with preserved and reduced LVEF, as well as in patients with newly diagnosed ADHF or with acute decompensation of chronic heart failure (CHF) compared with placebo, regardless of type 2 diabetes presence. The importance of the favorable results of the EMPULSE trial and its significance for clinical practice, which implies the early administration of empagliflozin for inpatients, is noted. A number of proposals have been adopted to accelerate the introduction of empagliflozin into clinical practice for patients with ADHF.

Keywords